drugset / Trial / NCT02568735

Dexketoprofen and Etoricoxib in Patients Undergoing Hip Arthroplasty

NCT02568735

Phase 4 Completed 24 enrolled Kuopio University Hospital
RandomizedParallel-groupOpen-labelTreatment

Summary

The main purpose of this study was to determine the plasma and central nervious system pharmacokinetics of dexketoprofen and etoricoxib. The secondary aim was to asses their effect on the concentrations of interleukin 6, prostaglandin E2 and other proinflammatory markers both in plasma and cerebrospinal fluid. Thirdly, the investigators aimed to evaluate their efficacy in postoperative pain treatment.

Timeline

Start
2013-01
Primary completion
2014-12
Completion
2014-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Dexketoprofen Small molecule 0.5 mg/kg Intravenous
Subject Etoricoxib Small molecule 60 mg Oral
Subject Etoricoxib Small molecule 90 mg Oral
Subject Etoricoxib Small molecule 120 mg Oral

Indications